By Malvika Gurung
Investing.com -- Shares of the pharmaceutical major Biocon (NS: BION ) tanked 7.86% to Rs 363.55 apiece at 10:31 am on Monday, after the company’s subsidiary Biocon Biologics (BBL) entered into a definitive agreement with the US-based global healthcare company Viatris (NASDAQ: VTRS ) to acquire its biosimilars business on Sunday.
The acquisition deal of Viatris’ biosimilars assets is worth up to $3.34 billion, of which nearly $2.34 billion will be paid in cash and the remaining amount through convertible preference shares.
Both the companies’ boards have given a green signal to the acquisition deal and the transaction is expected to complete by the second half of 2022.
Through the acquisition, BBL will get the global commercial infrastructure of Viatris in the developed and emerging markets.
This will expand BBL’s EBITDA base and bolster the overall financials. It will also create a unique fully integrated, world-leading biosimilars enterprise, stated the company.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.